Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bibo Zhang

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|July 30, 2024
Anti-CD22 Calicheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azacitidine in the Treatment of Mixed-Phenotype Acute Leukemia: A Case ReportKongfei Li, Yuxiao Wang, Renzhi Pei, et al.
Chemical Communications (Cambridge, England)|March 7, 2017
An iminodiacetate-modified conjugated polyelectrolyte for fluorescent labeling of histidine-tagged proteinsKai Cai, Ying Tan, Chunyan Tan, et al.
Journal of Materials Chemistry. B|April 9, 2020
Modulating aggregation-induced emission via a non-conjugated linkage of fluorophores to tetraphenylethenesXie Han, Bibo Zhang, Jianhua Chen, et al.
Hematology (Amsterdam, Netherlands)|November 22, 2012
Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemiaRenzhi Pei, Junjie Cao, Junxia Ma, et al.
Acta Biochimica Et Biophysica Sinica|February 23, 2023
A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathwayBibo Zhang, Bo Li, Yongsheng Xie, et al.
Acta Biochimica Et Biophysica Sinica|November 27, 2023
Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulationShuhan Jin, Bo Li, Bibo Zhang, et al.
Journal of Translational Medicine|November 28, 2023
The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathwayYingcong Wang, Sanfeng Dong, Ke Hu, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|July 30, 2024
Anti-CD22 Calicheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azacitidine in the Treatment of Mixed-Phenotype Acute Leukemia: A Case ReportKongfei Li, Yuxiao Wang, Renzhi Pei, et al.
Chemical Communications (Cambridge, England)|March 7, 2017
An iminodiacetate-modified conjugated polyelectrolyte for fluorescent labeling of histidine-tagged proteinsKai Cai, Ying Tan, Chunyan Tan, et al.
Journal of Materials Chemistry. B|April 9, 2020
Modulating aggregation-induced emission via a non-conjugated linkage of fluorophores to tetraphenylethenesXie Han, Bibo Zhang, Jianhua Chen, et al.
Hematology (Amsterdam, Netherlands)|November 22, 2012
Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemiaRenzhi Pei, Junjie Cao, Junxia Ma, et al.
Acta Biochimica Et Biophysica Sinica|February 23, 2023
A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathwayBibo Zhang, Bo Li, Yongsheng Xie, et al.
Acta Biochimica Et Biophysica Sinica|November 27, 2023
Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulationShuhan Jin, Bo Li, Bibo Zhang, et al.
Journal of Translational Medicine|November 28, 2023
The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathwayYingcong Wang, Sanfeng Dong, Ke Hu, et al.
Pageof 2